Advertisement
New Zealand markets closed
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NZD/USD

    0.5983
    -0.0023 (-0.38%)
     
  • NZD/EUR

    0.5536
    -0.0007 (-0.12%)
     
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    82.46
    +1.11 (+1.36%)
     
  • GOLD

    2,234.00
    +21.30 (+0.96%)
     
  • NASDAQ

    18,276.96
    -3.88 (-0.02%)
     
  • FTSE

    7,968.55
    +36.57 (+0.46%)
     
  • Dow Jones

    39,759.51
    -0.57 (-0.00%)
     
  • DAX

    18,499.24
    +22.15 (+0.12%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • NZD/JPY

    90.4000
    -0.3800 (-0.42%)
     

Davidson Kempner Capital Management LP : Form 8.3 - Horizon Therapeutics plc

Ap27

FORM 8.3

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.             KEY INFORMATION

(a)   Full name of discloser

Davidson Kempner Capital Management LP

(b)   Owner or controller of interests and short positions disclosed, if different from 1(a)

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c)   Name of offeror/offeree in relation to whose relevant securities this form relates

Use a separate form for each offeror/offeree

Horizon Therapeutics plc

(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)

 

(e)   Date position held/dealing undertaken

For an opening position disclosure, state the latest practicable date prior to the disclosure

31/1/2023

(f)    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

NO

2.             INTERESTS AND SHORT POSITIONS

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

ADVERTISEMENT


Ap28

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)

Class of relevant security
(Note 3)

$0.0001 ordinary shares

 

Interests

Short positions

Number

%

Number

%

(1)   Relevant securities owned and/or controlled

4,163,080

1.8227

 

 

(2)   Cash-settled derivatives

 

 

 

 

(3)   Stock-settled derivatives (including options) and agreements to purchase/ sell

 

 

 

 

Total

4,163,080

1.8227

 

 

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3.             DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.


(a)           Purchases and sales

Class of relevant
security

Purchase/sale

Number of
securities

Price per unit
(Note 5)

$0.0001 ordinary shares

Purchase

25,000

USD109.3063

$0.0001 ordinary shares

Purchase

10,000

USD110.4000

$0.0001 ordinary shares

Purchase

50,000

USD108.7892

$0.0001 ordinary shares

Purchase

15,700

USD108.7319

$0.0001 ordinary shares

Purchase

25,000

USD108.7906

$0.0001 ordinary shares

Purchase

9,300

USD108.6150

$0.0001 ordinary shares

Purchase

6,400

USD110.1700

$0.0001 ordinary shares

Purchase

20,000

USD109.3497

$0.0001 ordinary shares

Purchase

10,000

USD109.4905

$0.0001 ordinary shares

Purchase

25,000

USD109.5000

$0.0001 ordinary shares

Purchase

10,000

USD109.9972

$0.0001 ordinary shares

Purchase

10,000

USD109.8499

$0.0001 ordinary shares

Purchase

10,000

USD110.2500

$0.0001 ordinary shares

Purchase

3,600

USD110.1997

$0.0001 ordinary shares

Purchase

10,000

USD110.0000

$0.0001 ordinary shares

Purchase

10,000

USD109.9986

$0.0001 ordinary shares

Purchase

10,000

USD109.7500

Ap29

(b)           Cash-settled derivative transactions

Class of
relevant
security

Product
description
e.g. CFD

Nature of dealing
e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position

Number of
reference
securities
(Note 6)

Price
per unit
(Note 5)

 

 

 

 

 

(c)           Stock-settled derivative transactions (including options)

(i)            Writing, selling, purchasing or varying

Class of
relevant
security

Product
description e.g. call
option

Writing, purchasing, selling, varying
etc.

Number
of
securities
to which
option
relates
(Note 6)

Exercise
price per

unit

Type
e.g.
American,
European
etc.

Expiry
date

Option
money
paid/

received per unit

  

 

 

 

 

 

 

 

(ii)           Exercise

Class of
relevant
security

Product
description
e.g. call
option

Exercising/
exercised
against

Number of
securities

Exercise
price per
unit
(Note 5)

  

 

 

 

 

(d)           Other dealings (including transactions in respect of new securities) (Note 3)

Class of
relevant
security

Nature of dealing
e.g. subscription,
conversion, exercise

Details

Price per unit (if
applicable)
(Note 5)

 

 

 

 


Ap30

4.             OTHER INFORMATION

(a)           Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 None

(b)           Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 None

(c)           Attachments

Is a Supplemental Form 8 attached?

NO


Date of disclosure

01/02/2023

Contact name

Sharayna Desouza

Telephone number

02072926764